Alembic gets USFDA tentative nod for drug for high BP

Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg

97
USFDA
Picture: Pixabay

Last Updated on December 10, 2021 by The Health Master

Alembic Pharmaceuticals today received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Selexipag tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug (RLD) product Uptravi tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg, of Actelion Pharmaceuticals, according to a statement from the company.

The statement further said that Selexipag tablets are indicated for the treatment of Pulmonary Arterial Hypertension (PAH) to delay disease progression and reduce the risk of hospitalisation for PAH.

Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg have an estimated market size of $461 million for twelve months ending September 2021, according to IQVIA.

Alembic has received year to date (YTD) 15 approvals (11 final approvals and four tentative approvals) and a cumulative total of 154 ANDA approvals (134 final approvals and 20 tentative approvals) from the USFDA, it concluded.

Biocon gets USFDA nod for Mycophenolic Acid

Morepen gets USFDA nod for anti-allergy drug

USFDA approves new drug to help identify cancer lesions

USFDA grants accelerated approval for Vosoritide for injection

Zydus Cadila gets USFDA nod to market generic Cancer drug in US

Aleor Derma gets USFDA nod for Antibacterial Cream: Alembic

Procedure for registration of Medical Devices: CDSCO

Procedure to obtain license for Commercial Testing Laboratories

India’s first generic drug for cancer treatment launched

Govt sets up Task Force for Nutraceutical sector

Pricing Policy may change to regulate base prices of 50% of…

NPPA fixes retail price of 20 formulations: December 2021

IPC adds these 9 new IP impurities standards

Lok Sabha passes NIPER (Amendment) Bill 2021

India and Pharmacy Education: Chapter: 10

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner